$463 Million is the total value of Octagon Capital Advisors LP's 24 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 35.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $118,898,000 | +24.4% | 2,340,059 | +15.8% | 25.70% | +38.2% |
| RCUS | Buy | ARCUS BIOSCIENCES INC | $78,584,000 | -7.3% | 2,489,974 | +18.8% | 16.99% | +3.0% |
| CLDX | CELLDEX THERAPEUTICS INC NEW | $25,933,000 | -11.9% | 761,398 | 0.0% | 5.61% | -2.1% | |
| FDMT | Buy | 4D MOLECULAR THERAPEUTICS IN | $23,691,000 | -30.4% | 1,566,895 | +1.0% | 5.12% | -22.7% |
| BBIO | Buy | BRIDGEBIO PHARMA INC | $23,015,000 | -21.9% | 2,267,486 | +28.3% | 4.98% | -13.3% |
| GOSS | Buy | GOSSAMER BIO INC | $22,248,000 | +30.0% | 2,563,138 | +69.4% | 4.81% | +44.4% |
| KDNY | Buy | CHINOOK THERAPEUTICS INC | $22,188,000 | +172.1% | 1,356,250 | +171.2% | 4.80% | +202.3% |
| KROS | KEROS THERAPEUTICS INC | $18,501,000 | -7.1% | 340,214 | 0.0% | 4.00% | +3.3% | |
| STOK | Buy | STOKE THERAPEUTICS INC | $17,123,000 | -8.9% | 813,456 | +3.8% | 3.70% | +1.2% |
| IMAB | I MABsponsored ads | $17,047,000 | -65.7% | 1,049,691 | 0.0% | 3.68% | -61.9% | |
| ITOS | ITEOS THERAPEUTICS INC | $14,506,000 | -30.9% | 450,776 | 0.0% | 3.14% | -23.2% | |
| VERA | Sell | VERA THERAPEUTICS INCcl a | $13,507,000 | -24.7% | 575,000 | -14.3% | 2.92% | -16.3% |
| ARVN | ARVINAS INC | $12,013,000 | -18.1% | 178,500 | 0.0% | 2.60% | -9.0% | |
| HZNP | New | HORIZON THERAPEUTICS PUB L | $10,521,000 | – | 100,000 | +100.0% | 2.28% | – |
| IPSC | Sell | CENTURY THERAPEUTICS INC | $8,288,000 | -25.6% | 658,266 | -6.3% | 1.79% | -17.4% |
| IMVT | Buy | IMMUNOVANT INC | $8,127,000 | +66.5% | 1,475,000 | +157.5% | 1.76% | +84.9% |
| SURF | New | SURFACE ONCOLOGY INC | $6,762,000 | – | 2,300,000 | +100.0% | 1.46% | – |
| RNA | Sell | AVIDITY BIOSCIENCES INC | $5,941,000 | -44.0% | 321,641 | -28.0% | 1.28% | -37.9% |
| DYN | Sell | DYNE THERAPEUTICS INC | $5,064,000 | -27.0% | 525,284 | -10.0% | 1.10% | -18.9% |
| XBI | New | SPDR SER TRs&p biotech | $5,015,000 | – | 55,800 | +100.0% | 1.08% | – |
| RXDX | Sell | PROMETHEUS BIOSCIENCES INC | $3,021,000 | -61.8% | 80,000 | -60.0% | 0.65% | -57.6% |
| OMEGA THERAPEUTICS INC | $1,101,000 | -44.9% | 176,470 | 0.0% | 0.24% | -38.8% | ||
| CNTB | CONNECT BIOPHARMA HLDGS LTDads | $845,000 | -41.4% | 279,921 | 0.0% | 0.18% | -34.9% | |
| AMAM | Sell | AMBRX BIOPHARMA INCsponsored ads | $616,000 | -79.8% | 149,400 | -55.7% | 0.13% | -77.5% |
| CMPX | Exit | COMPASS THERAPEUTICS INC | $0 | – | -240,000 | -100.0% | -0.15% | – |
| OLMA | Exit | OLEMA PHARMACEUTICALS INC | $0 | – | -231,417 | -100.0% | -0.42% | – |
| JYAC | Exit | JIYA ACQUISITION CORP | $0 | – | -300,000 | -100.0% | -0.57% | – |
| GLUE | Exit | MONTE ROSA THERAPEUTICS INC | $0 | – | -150,000 | -100.0% | -0.60% | – |
| HLXA | Exit | HELIX ACQUISITION CORP | $0 | – | -400,000 | -100.0% | -0.77% | – |
| CRDF | Exit | CARDIFF ONCOLOGY INC | $0 | – | -982,753 | -100.0% | -1.15% | – |
| Exit | CYTEK BIOSCIENCES INC | $0 | – | -400,000 | -100.0% | -1.27% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APELLIS PHARMACEUTICALS INC | 12 | Q3 2023 | 33.2% |
| ARCUS BIOSCIENCES INC | 12 | Q3 2023 | 18.1% |
| CELLDEX THERAPEUTICS INC NEW | 12 | Q3 2023 | 10.1% |
| GOSSAMER BIO INC | 12 | Q3 2023 | 6.2% |
| 4D MOLECULAR THERAPEUTICS IN | 10 | Q1 2023 | 6.6% |
| BRIDGEBIO PHARMA INC | 10 | Q3 2023 | 6.6% |
| AVIDITY BIOSCIENCES INC | 10 | Q1 2023 | 3.8% |
| VERA THERAPEUTICS INC | 9 | Q2 2023 | 3.5% |
| DYNE THERAPEUTICS INC | 9 | Q3 2023 | 3.5% |
| STOKE THERAPEUTICS INC | 9 | Q2 2023 | 3.7% |
View Octagon Capital Advisors LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-06 |
| SC 13G/A | 2024-02-05 |
| SC 13G | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-25 |
| 13F-HR | 2022-11-14 |
View Octagon Capital Advisors LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.